Experts Weigh In on What FDA's Removal of REMS for CAR T Means for Patients, Pharmacists

FDA OKs label changes to boost CAR T-cell therapy use for cancer

The U.S. Food and Drug Administration (FDA) has approved label updates for two Bristol Myers Squibb (BMS) CAR T-cell therapies, both for the treatment of rare cancers: Abecma (idecabtagene vicleucel) for multiple myeloma, and Breyanzi (lisocabtagene maraleucel) for large B-cell lymphoma, known as LBCL, and other lymphomas. These label updates scale back certain patient monitoring requirements related to driving restrictions and the time spent ne…

Experts Weigh In on What FDA's Removal of REMS for CAR T Means for Patients, Pharmacists

Debra Patt, MD, PhD, MBA, and Houston Holmes, MD, discuss the ramifications of the FDA's removal of REMS requirements for approved chimeric antigen receptor (CAR) T-cell (CAR T) therapies.